All In MedTech

FDA Clearance Tracker · P960009-S219

MEDTRONIC DBS THERAPY FOR EPILEPSY

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 27, 2018 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 27, 2018

Approved

Time to decision

1,158 days

Received Feb 24, 2015. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P960009-S219
Device name
MEDTRONIC DBS THERAPY FOR EPILEPSY
Applicant location
Minneapolis, MN
Received
Feb 24, 2015
Decided
Apr 27, 2018
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P960009

Device type

Device class
Class III

Every decision under product code MBX

FDA's approval statement

As written in FDA's record.

Approval to expand the indications for the Medtronic DBS system to include Epilepsy. Bilateral stimulation of the anterior nucleus of the thalamus (ANT) using the Medtronic DBS System for Epilepsy is indicated as an adjunctive therapy for reducing the frequency of seizures in individuals 18 years of age or older diagnosed with epilepsy characterized by partial-onset seizures, with or without secondary generalization, that are refractory to three or more antiepileptic medications.The Medtronic DBS System for Epilepsy has demonstrated safety and effectiveness for patients who average six or more seizures per month over the three most recent months prior to implant of the DBS system (with no more than 30 days between seizures). The Medtronic DBS System for Epilepsy has not been evaluated in patients with less frequent seizures.

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.